Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A092105

CTO #:

103992

NCT Number:

NCT05904080

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lip, Oral Cavity and Pharynx

Study Objectives:

To determine if the progression-free survival (PFS) of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi). To compare safety and tolerability between the two arms (CTCAE v5.0.). To compare overall response rate (ORR) between the two arms via both RECIST v1.1 and iRECIST criteria. To compare overall survival (OS) between the two arms.To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)